

Neurotech Formalises Strategic Partnership with Fenix Innovation Group

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announced the execution of a Strategic Collaboration Agreement ("Agreement") with Fenix Innovation Group ("Fenix"), a leading contract research organisation ("CRO") based in Melbourne, Australia.

On 10 April 2024, Neurotech announced the signing of a binding term sheet for the strategic collaboration with Fenix who will work exclusively with Neurotech in the medicinal cannabis field with the development of the Company's broad spectrum cannabinoid drug therapy NTI164 for neurological disorders. The execution of the definitive Agreement now formalises the partnership with Fenix and replaces the binding term sheet.

Dr Thomas Duthy, Executive Director of Neurotech said "We are pleased to have completed this definitive Agreement within a timely fashion and we look forward to working even more closely with Fenix on our planned regulatory submissions, clinical trial protocol development and manufacturing."

The key terms of the Agreement between Fenix and Neurotech are set out in Appendix 1.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Appendix 1 – Key Terms of Strategic Collaboration Agreement with Fenix Innovation Group

<p>Purpose</p>	<p>The Agreement fully sets out the terms of the strategic collaboration between Neurotech and Fenix relating to the exclusive development and commercialisation within the medicinal cannabis field of Neurotech's broad spectrum cannabinoid therapy NTI164 ("NTI164") for neurological disorders and the services which Fenix will provide to Neurotech in this respect.</p>
<p>Material Terms of Performance Rights</p>	<p>Subject to approval from Neurotech shareholders to be sought at its 2024 Annual General Meeting (or an earlier General Meeting), the following securities are proposed to be issued to Fenix or its nominees in consideration for its entry into the Agreement and to incentivise Fenix over the course of the strategic collaboration between Fenix and NTI:</p> <ul style="list-style-type: none"> • 10 million Neurotech ordinary shares which will be subject to voluntary escrow for 12 months from the date of issue • 7.5 million Neurotech performance rights to vest into shares upon NTI164 receiving an Orphan Drug Designation in the US for any paediatric neurological indication • 7.5 million Neurotech performance rights to vest into shares upon NTI164 receiving an Orphan Drug Designation in the European Union ('EU') for any paediatric neurological indication • 5 million Neurotech performance rights to vest into shares upon Neurotech receiving either a US FDA IND or an EU Competent Authority clearance for a human clinical trial in any paediatric neurological indication in respect of NTI164 • 10 million Neurotech performance rights to vest into shares upon: <ul style="list-style-type: none"> ○ Neurotech signing a licence deal with a 3rd party for any of the US, EU, Japanese, Canadian or Australian markets with a view to gaining registration and subsequent sales of NTI164, and ○ the shares of Neurotech having a trading VWAP of a minimum of 25 cents over 5 consecutive days in which trades in the shares occurred on ASX. • 20 million Neurotech performance rights to vest into shares upon: <ul style="list-style-type: none"> ○ NTI164 receiving a TGA approval (provisional or otherwise) allowing the Company to market and sell NTI164 in Australia for the treatment of any paediatric neurological disorder, and ○ the shares of Neurotech having a trading VWAP of a minimum of 30 cents over 5 consecutive days in which trades in the shares occurred on ASX. <p>The Performance Rights will expire three years from the date of their issue and will otherwise be issued on terms and conditions compliant with the ASX Listing Rules and ASX Guidance Note 19.</p> <p>Unconverted Performance Rights will immediately lapse upon termination of the Agreement.</p>

Termination	90 days' notice by either party, or immediately for cause.
General	The other terms of the Agreement are standard for an agreement of this nature including intellectual property protections, warranties and indemnities in favour of Neurotech.

VWAP – volume weighted average price
 FDA – Food and Drug Administration
 IND – investigational new drug
 TGA- Therapeutic Goods Administration